Calcium carboxymethylcellulose veterinary grade is a partially substituted carboxymethyl ether of cellulose in which the sodium cation of the polymer has been partially exchanged with calcium. Although the commercial designation includes the term API, the monograph function of calcium carboxymethylcellulose is that of a pharmaceutical excipient: disintegrant, binder, suspending agent, and stabiliser. The material is released as an off-white to cream, odourless powder with a bulk density of 0.35–0.60 g/mL and a tapped density of 0.55–0.90 g/mL for direct-compression models; spray-dried grades exhibit lower bulk density and faster hydration, while roller-compacted grades provide higher flowability for low-fill-weight capsule dosators. Model designations CaCMC-VET-300, CaCMC-VET-800, CaCMC-VET-2000, and CaCMC-VET-4000 encode the nominal apparent viscosity of a 1.0% w/v aqueous dispersion at 25 °C, measured with a Brookfield LV viscometer at 30 rpm according to Ph. Eur. 2.2.10. The veterinary grade is controlled to compendial purity criteria for carboxymethylcellulose calcium where a monograph exists, with additional bacterial endotoxin and heavy metal restrictions for parenteral and feed-chain use. The product is used at 0.5–5.0% w/w as a binder-disintegrant in tablets, 0.2–1.0% w/v as a suspending agent in injectable suspensions, 1.0–4.0% w/w in oral powders and granules, and 2.0–5.0% w/w in medicated premixes and liquid feed supplements. This grade is distinguished from unmodified sodium carboxymethylcellulose by lower aqueous solubility, lower sodium assay, and a calcium-dependent thixotropic response under shear.

What Distinguishes This Grade from Unmodified Sodium Carboxymethylcellulose or Croscarmellose Sodium?

The calcium salt forms a swollen, thixotropic colloidal gel rather than a clear solution at neutral pH. The lower solubility reduces surface filming during tablet compression and permits use as a disintegrant at 1.0–5.0% w/w without the sticking tendency observed with fully soluble sodium CMC. In addition, the calcium counterion contributes to interchain ionic association. This produces a higher yield stress at equivalent polymer concentration, as determined by rotational rheometry at 25 °C, but lower hygroscopicity; the latter is relevant in medicated premixes exposed to ambient humidity cycles. The sodium assay is below 1.0% w/w, compared with 6.5–9.5% w/w sodium content in typical sodium CMC, which reduces total sodium load in feed or parenteral products. The calcium content, determined by complexometric titration after ashing, is generally 5.0–9.0% w/w on the dried basis.

Croscarmellose sodium is a more aggressive insoluble superdisintegrant with a high swelling volume, but it is less suited to injectable suspension stabilisation and may introduce a higher sodium counterion level. Calcium CMC hydrates more slowly and is therefore preferred when the same excipient must function as a binder in wet granulation and as a suspending agent in oral solutions. Direct comparisons under USP <701> disintegration conditions show that calcium CMC achieves complete disintegration in 5–15 min at 2.0–4.0% w/w in typical veterinary tablet matrices, although published data for multi-enzyme gastric simulation remains limited.

Viscosity, Substitution Pattern, and Compendial Residue Limits

Selection of a release batch begins with the rheological profile and degree of substitution. The degree of carboxymethyl substitution is typically 0.60–0.85, determined by a compendial etherification assay; lower substitution reduces cold-water hydration, while higher substitution increases gel clarity and salt tolerance. The apparent viscosity of the dispensed 1.0% w/v aqueous dispersion at 25 °C is the primary release criterion and is selected according to the dosage form: 300–800 mPa·s for injectable suspensions where syringeability sets an upper limit, 1500–2000 mPa·s for tablet wet granulation and oral solutions, and 3000–4000 mPa·s for feed premixes requiring shear-stable suspension in liquid carriers. The powder moisture content is controlled to ≤10.0% because residual moisture above this limit accelerates microbial growth during ambient storage of medicated premixes.

The release specification profile in Table 1 is aligned with harmonised pharmacopoeial methods. The user should verify current monograph limits for the intended jurisdiction.

On a rotary tablet press equipped with 10 mm flat-faced B tooling, compression force is typically maintained between 8 kN and 18 kN for matrices containing 3.0% w/w CaCMC-VET-800, 96.0% w/w microcrystalline cellulose, and 1.0% w/w magnesium stearate. Under these conditions, disintegration is verified according to USP <701>; hardness is usually controlled to 60–90 N to balance disintegration and friability. The material acts as both binder and disintegrant because the partially substituted particles swell anisotropically under contact with water; swelling is more gradual than croscarmellose sodium but produces lower friability in highly hygroscopic actives. For wet granulation, a 2.0% w/w dry addition before high-shear mixing or a 1.0% w/w aqueous dispersion added during granulation at impeller speed 300 rpm and chopper speed 1500 rpm reduces oversize fraction after cone milling through a 0.8 mm screen. Batch-to-batch variation in particle size should be monitored by laser diffraction: direct-compression grades require D90 ≤150 μm, and capsule-fill grades require D90 ≤75 μm to prevent stratification in low-fill-weight powder dosators.

When Injectable Suspension Formulations Require Controlled Thixotropy and Low Endotoxin Load

For parenteral veterinary formulations, the injectable grade is processed under controlled bioburden conditions and released with a bacterial endotoxin limit of ≤0.5 EU/mg by Ph. Eur. 2.6.14. Suspensions are typically prepared at 0.2–1.0% w/v polymer, hydrated under vacuum to remove entrained air, and homogenised with a high-shear rotor-stator mixer at 8000–12000 rpm until the dispersion passes a 200 μm screen. Terminal steam sterilisation at 121 °C for 15 min may reduce apparent viscosity by 10–30% depending on autoclave load and initial molecular weight; therefore, viscosity overage and post-sterilisation rheological verification are part of release. Published data for this specific configuration is limited, and each formulation must be validated under the intended container-closure system. The calcium salt is preferred over sodium CMC in parenteral products when sodium restriction is required or when electrolyte tolerance is needed.

In oral powders and granules, the material is dry-blended at 1.0–4.0% w/w in a ribbon blender or tumble mixer; blend uniformity should be verified according to USP <905> uniformity of dosage units and should target an RSD of ≤5.0% for active drug content. The powder grade is selected with a controlled particle size distribution and low fines to reduce dusting during open transfer. For medicated feed premixes, the calcium CMC thixotrope is mixed at 2.0–5.0% w/w with the active premix before dilution into final feed; the hydration rate in hard water or buffered ruminal fluid can be slowed by the calcium counterion, which reduces lumping in non-agitated water tanks. Oral solutions are prepared by dispersing the polymer in cold water with high-shear mixing, followed by the addition of buffer salts and preservatives; the pH is adjusted to 5.0–7.0 to maintain viscosity stability for 24 h at 25 °C. Table 2 summarises the application matrix.

During high-shear wet granulation of hygroscopic veterinary actives, granulation endpoint is commonly determined by impeller power consumption rather than fixed time because the calcium CMC gel phase alters mass viscosity nonlinearly once water addition exceeds 8.0% w/w of dry granulate. In a 25 L high-shear granulator with impeller 300 rpm and chopper 1500 rpm, the addition of 1.5% w/w CaCMC-VET-2000 as dry binder and 7.0–9.0% w/w purified water produces granules with a typical d50 of 150–250 μm after tray drying at 50 °C to ≤2.0% residual moisture. If the moisture content exceeds 12.0% during granulation, the mass may undergo over-granulation, resulting in oversized agglomerates that require re-milling and compromise tablet content uniformity. In-process moisture is therefore monitored by loss-on-drying at 105 °C or near-infrared reflectance, and batch records include both impeller torque and granulate temperature. Published data for this specific configuration is limited, and scale-up should be confirmed with a factorial design.

Calcium Counterion Bridging Governs Long-Term Stability in Hard-Water Premix Systems

The calcium ion forms labile bridges between carboxymethyl ether groups on adjacent cellulose chains. This association increases the elastic modulus of the hydrated gel and retards syneresis during static storage, which is advantageous for premixes suspended in molasses blocks or liquid feed supplements. However, in phosphate-buffered veterinary injections, excess phosphate may compete with the carboxylate sites and reduce the yield stress; a compatibility test in the target buffer at 25 °C and 40 °C over 72 h should be performed before locking formulation composition. The calcium content, typically 5.0–9.0% w/w on the dried basis by complexometric titration, must be controlled because an excessively high calcium-to-polymer ratio increases brittleness in dried granules and reduces redispersibility. For tablets and capsules, the same crosslinking can slow disintegration if the polymer is overcompressed above 18 kN compression force. Therefore, the practical upper addition is 5.0% w/w for tablets; above this threshold, the disintegrant may act as a sustained-release matrix former rather than an immediate-release disintegrant.

In storage, the powder should be kept in tightly closed containers at 15–25 °C; exposure to relative humidity above 60% for more than 24 h may increase moisture content beyond the 10.0% release limit and initiate caking. Pre-drying at 60 °C for 2 h is used when opened containers are returned to the dispensary. The material is not compatible with strong oxidising agents, and prolonged contact with concentrated acids or alkalis degrades the cellulose backbone, reducing viscosity irreversibly. Finished veterinary drug product manufacture should follow 21 CFR 211 for current good manufacturing practice.